158 related articles for article (PubMed ID: 37669914)
1. Pretreatment eosinophil counts as a predictive biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Takeuchi E; Kondo K; Okano Y; Ichihara S; Kunishige M; Kadota N; Machida H; Hatakeyama N; Naruse K; Ogino H; Nokihara H; Shinohara T; Nishioka Y
Thorac Cancer; 2023 Oct; 14(30):3042-3050. PubMed ID: 37669914
[TBL] [Abstract][Full Text] [Related]
2. An increased relative eosinophil count as a predictive dynamic biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Takeuchi E; Ogino H; Kondo K; Okano Y; Ichihara S; Kunishige M; Kadota N; Machida H; Hatakeyama N; Naruse K; Nokihara H; Shinohara T; Nishioka Y
Thorac Cancer; 2024 Jan; 15(3):248-257. PubMed ID: 38087769
[TBL] [Abstract][Full Text] [Related]
3. Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer.
Takeuchi E; Kondo K; Okano Y; Kunishige M; Kondo Y; Kadota N; Machida H; Hatakeyama N; Naruse K; Ogino H; Nokihara H; Shinohara T; Nishioka Y
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3139-3147. PubMed ID: 35871700
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
[TBL] [Abstract][Full Text] [Related]
5. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors.
Mota JM; Teo MY; Whiting K; Li HA; Regazzi AM; Lee CH; Funt SA; Bajorin D; Ostrovnaya I; Iyer G; Rosenberg JE
J Immunother; 2021 Sep; 44(7):248-253. PubMed ID: 34081050
[TBL] [Abstract][Full Text] [Related]
7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
8. Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Kao C; Powers E; Wu Y; Datto MB; Green MF; Strickler JH; Ready NE; Zhang T; Clarke JM
Clin Lung Cancer; 2021 Nov; 22(6):500-509. PubMed ID: 33972172
[TBL] [Abstract][Full Text] [Related]
9. Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy.
Passaro A; Mancuso P; Gandini S; Spitaleri G; Labanca V; Guerini-Rocco E; Barberis M; Catania C; Del Signore E; de Marinis F; Bertolini F
Clin Transl Oncol; 2020 Apr; 22(4):603-611. PubMed ID: 31254252
[TBL] [Abstract][Full Text] [Related]
10. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
[TBL] [Abstract][Full Text] [Related]
11. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
[TBL] [Abstract][Full Text] [Related]
12. 5-Year survival in Danish patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy.
Bjørnhart B; Mouritzen MT; Kristiansen C; Schytte T; Wedervang K; Pøhl M; Holmskov Hansen K
Acta Oncol; 2023 Aug; 62(8):861-870. PubMed ID: 37534770
[TBL] [Abstract][Full Text] [Related]
13. Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB.
Chen J; Wei S; Zhao T; Zhang X; Wang Y; Zhang X
Dis Markers; 2022; 2022():7137357. PubMed ID: 35945957
[TBL] [Abstract][Full Text] [Related]
14. A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.
Ayers KL; Ma M; Debussche G; Corrigan D; McCafferty J; Lee K; Newman S; Zhou X; Hirsch FR; Mack PC; Liu JJ; Schadt EE; Chen R; Li SD
BMC Cancer; 2021 Apr; 21(1):441. PubMed ID: 33882890
[TBL] [Abstract][Full Text] [Related]
15. Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy.
Guo Y; Wei L; Patel SH; Lopez G; Grogan M; Li M; Haddad T; Johns A; Ganesan LP; Yang Y; Spakowicz DJ; Shields PG; He K; Bertino EM; Otterson GA; Carbone DP; Presley C; Kulp SK; Mace TA; Coss CC; Phelps MA; Owen DH
Clin Lung Cancer; 2022 Jun; 23(4):345-355. PubMed ID: 35131184
[TBL] [Abstract][Full Text] [Related]
16. Association between peripheral eosinophils and clinical outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
Okauchi S; Shiozawa T; Miyazaki K; Nishino K; Sasatani Y; Ohara G; Kagohashi K; Sato S; Kodama T; Satoh H; Hizawa N
Pol Arch Intern Med; 2021 Feb; 131(2):152-160. PubMed ID: 33491942
[TBL] [Abstract][Full Text] [Related]
17. Real-world outcomes of 18,186 metastatic solid tumor outpatients: Baseline blood cell counts correlate with survival after immune checkpoint inhibitor therapy.
Goldschmidt JH; Chou LN; Chan PK; Chen L; Robert N; Kinsey J; Pitts K; Nestor M; Rock EP; Lazarus HM
Cancer Med; 2023 Nov; 12(22):20783-20797. PubMed ID: 37962239
[TBL] [Abstract][Full Text] [Related]
18. Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer.
Jung EH; Jang HR; Kim SH; Suh KJ; Kim YJ; Lee JH; Chung JH; Kim M; Keam B; Kim TM; Kim DW; Heo DS; Lee JS
Thorac Cancer; 2021 Mar; 12(5):619-630. PubMed ID: 33458968
[TBL] [Abstract][Full Text] [Related]
19. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
20. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
Mountzios G; Samantas E; Senghas K; Zervas E; Krisam J; Samitas K; Bozorgmehr F; Kuon J; Agelaki S; Baka S; Athanasiadis I; Gaissmaier L; Elshiaty M; Daniello L; Christopoulou A; Pentheroudakis G; Lianos E; Linardou H; Kriegsmann K; Kosmidis P; El Shafie R; Kriegsmann M; Psyrri A; Andreadis C; Fountzilas E; Heussel CP; Herth FJ; Winter H; Emmanouilides C; Oikonomopoulos G; Meister M; Muley T; Bischoff H; Saridaki Z; Razis E; Perdikouri EI; Stenzinger A; Boukovinas I; Reck M; Syrigos K; Thomas M; Christopoulos P
ESMO Open; 2021 Oct; 6(5):100254. PubMed ID: 34481329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]